Description
BSA TR30 30 mg — Research Description
BSA TR30 is a research-designated synthetic dual agonist peptide (known as Tirzepatide) studied in metabolic and endocrine research. It is designed to interact with both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, making it relevant for investigating multi-pathway metabolic regulation in controlled laboratory environments.
What It Is
BSA TR30 is a long-acting peptide analog engineered to target incretin hormone receptors. In research settings, it is used to explore dual receptor activation, hormonal signaling, and metabolic pathway interactions.
What It Is Used For (Research Context)
In laboratory settings, BSA TR30 is used to study:
- Dual activation of GIP and GLP-1 receptor pathways
- Metabolic signaling and pathway integration
- Glucose metabolism and insulin-related mechanisms
- Energy balance and nutrient utilization
- Hormone–receptor interaction dynamics
- Endocrine system regulation in experimental models
Chemical & Structural Properties
- Compound designation: BSA TR30
- Reference compound: Tirzepatide
- Peptide class: Dual receptor agonist (GIP/GLP-1)
- Form: Lyophilized powder
- Quantity: 30 mg per vial
- Purity: ≥99% (research-grade)
- Engineered for enhanced stability and extended activity
Laboratory & Research Applications
Used strictly in controlled environments for:
- Metabolic and endocrine research studies
- Peptide–receptor interaction assays
- Cell culture and in vivo experimental models
- Biochemical and molecular pathway analysis
- Pharmacological and peptide development research
Handling & Storage (Research Settings)
- Store at −20°C or lower
- Protect from light, heat, and moisture
- Reconstitute using sterile laboratory-grade solvents or buffers
- Avoid repeated freeze–thaw cycles
- Follow standard aseptic laboratory procedures
Important Notice
This product contains BSA TR30 and is intended strictly for research purposes only.
It is not for human consumption.

Reviews
There are no reviews yet.